Troriluzole

Generic Name: Troriluzole

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₆F_₃N_₅O_₄S

CAS Number: 1926203-09-9

Unique Ingredient Identifier: S7H48S6K7H

Background: Troriluzole is under investigation in clinical trial NCT03701399 (Troriluzole in Adult Subjects With Spinocerebellar Ataxia).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

Early Phase 1

Not yet recruiting

Conditions: Recurrent Glioblastoma
Brain Tumor
Glioblastoma

Interventions: Drug: Troriluzole

First Posted Date: 2024-08-13

Last Posted Date: 2024-08-14

Lead Sponsor: Eudocia Quant Lee, MD

Target Recruit Count: 27

Registration Number: NCT06552260

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)

Conditions: SCA
Spinocerebellar Ataxias

First Posted Date: 2023-09-13

Last Posted Date: 2024-11-05

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Registration Number: NCT06034886

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Phase 2

Terminated

Conditions: Melanoma
Metastatic Melanoma

Interventions: Drug: Ipilimumab
Drug: Nivolumab
Drug: Troriluzole
Drug: Placebo

First Posted Date: 2021-05-25

Last Posted Date: 2024-03-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 1

Registration Number: NCT04899921

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

Phase 3

Recruiting

Conditions: Obsessive-Compulsive Disorder

Interventions: Drug: Placebo
Drug: Troriluzole

First Posted Date: 2021-01-05

Last Posted Date: 2024-04-19

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Target Recruit Count: 700

Registration Number: NCT04693351

Locations: 🇺🇸
Om Research LLC, Lancaster, California, United States
🇺🇸
CI Trials, Riverside, California, United States
🇺🇸
Clintex Research, Miami, Florida, United States

and more 107 locations

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Phase 3

Recruiting

Conditions: Obsessive-Compulsive Disorder

Interventions: Drug: Troriluzole
Drug: Placebo

First Posted Date: 2020-11-23

Last Posted Date: 2024-04-19

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Target Recruit Count: 700

Registration Number: NCT04641143

Locations: 🇺🇸
Global Clinical Trials, Costa Mesa, California, United States
🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 82 locations

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Phase 2

Recruiting

Conditions: Glioblastoma

Interventions: Drug: VAL-083
Drug: VT1021
Drug: Troriluzole
Drug: Temozolomide
Drug: Regorafenib
Drug: Paxalisib
Biological: ADI-PEG 20
Drug: Lomustine
Radiation: Radiation

First Posted Date: 2019-05-31

Last Posted Date: 2024-12-02

Lead Sponsor: Global Coalition for Adaptive Research

Target Recruit Count: 1030

Registration Number: NCT03970447

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸
Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States

and more 59 locations

Randomized Trial of Adult Participants With Generalized Anxiety Disorder

Phase 3

Completed

Conditions: Generalized Anxiety Disorder

Interventions: Drug: Troriluzole
Drug: Placebo

First Posted Date: 2019-02-04

Last Posted Date: 2024-05-08

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Target Recruit Count: 881

Registration Number: NCT03829241

Locations: 🇺🇸
CalNeuro Research Group, Los Angeles, California, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Boston Clinical Trials, Boston, Massachusetts, United States

and more 45 locations

Troriluzole in Adult Subjects With Spinocerebellar Ataxia

Phase 3

Active, not recruiting

Conditions: Spinocerebellar Ataxia Type 1
Spinocerebellar Ataxia Type 2
Spinocerebellar Ataxia Type 3
Spinocerebellar Ataxia Type 6
Spinocerebellar Ataxia Type 7
Spinocerebellar Ataxia Type 10
Spinocerebellar Ataxias
Spinocerebellar Ataxia Type 8

Interventions: Drug: troriluzole
Drug: Placebos

First Posted Date: 2018-10-10

Last Posted Date: 2024-01-25

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Target Recruit Count: 218

Registration Number: NCT03701399

Locations: 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 20 locations

Study of BHV-4157 in Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Placebo oral capsule
Drug: troriluzole

First Posted Date: 2018-07-30

Last Posted Date: 2023-12-06

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Target Recruit Count: 350

Registration Number: NCT03605667

Locations: 🇺🇸
Northern Light Acadia Hospital, Bangor, Maine, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Brain Matters Research, Delray Beach, Florida, United States

and more 41 locations

Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder

Phase 2

Active, not recruiting

Conditions: Obsessive-Compulsive Disorder

Interventions: Drug: Placebo
Drug: Troriluzole

First Posted Date: 2017-10-02

Last Posted Date: 2023-09-08

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Target Recruit Count: 426

Registration Number: NCT03299166

Locations: 🇺🇸
CalNeuro Research Group, Los Angeles, California, United States
🇺🇸
Desert Valley Research, Rancho Mirage, California, United States
🇺🇸
Gulfcoast Clinical Research Center, Fort Myers, Florida, United States

and more 52 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy